Serum alpha-synuclein in restless legs syndrome

Area of Science:

• Neuroscience
• Biochemistry
• Clinical Medicine

Background:

• Restless Legs Syndrome (RLS) is a neurological disorder characterized by an urge to move the legs.
• The pathophysiology of RLS is not fully understood, but dopaminergic dysfunction is implicated.
• Alpha-synuclein (α-syn) is a protein involved in neuronal function and implicated in neurodegenerative diseases.

Purpose of the Study:

• To investigate the correlation between serum alpha-synuclein (α-syn) concentrations and Restless Legs Syndrome (RLS).
• To evaluate the effect of intravenous (IV) iron supplementation on serum α-syn levels in RLS patients.

Main Methods:

• Serum α-syn levels were measured using ELISA in 113 RLS patients and 45 age-matched controls.
• A subset of nine RLS patients received IV iron, with pre- and post-treatment blood samples collected.
• Serum ferritin levels were also assessed.

Main Results:

• RLS patients exhibited significantly lower serum α-syn levels (7.7 ng/mL) compared to controls (10.7 ng/mL).
• Low serum ferritin (<75 μg/L) was observed in 39.8% of RLS patients.
• In patients treated with IV iron, a positive correlation between fold change in α-syn and ferritin was noted (R=0.7, p<0.05).
• A significant temporal decline in both α-syn and ferritin was observed post-IV iron treatment (p=0.023, R=-.739).

Conclusions:

• Serum α-syn levels are decreased in RLS patients compared to healthy individuals.
• IV iron treatment in RLS patients correlated with an increase in serum α-syn levels and ferritin.
• The observed correlation suggests a potential link between iron levels, α-syn, and dopaminergic transmission in RLS pathophysiology.